Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 3,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Prostate Cancer
Interventions: Gene Modified T Cells; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Ependymoma
Interventions: Irradiation, Surgery, ^1^8F-Fluorodeoxyglucose, ^1^1C-methionine, Photon therapy, Proton therapy; Radiation · Procedure · Drug + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 21 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Adenocarcinoma, Pancreatic Neoplasms
Interventions: X-82, Everolimus; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: St Louis, Missouri • Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: CYB003, Psychotherapy, Placebo, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey

Conditions: Lymphoma
Interventions: Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX); Procedure · Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 19
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more

Conditions: Critical Limb Ischemia
Interventions: RJX, Placebo; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Sham transcranial direct current stimulation 4 mA, Transcranial direct current stimulation 4 mA; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Type 1 Diabetes Mellitus
Interventions: Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Concord, California • Encino, California • Escondido, California + 35 more

Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: Pemetrexed, Carboplatin, demcizumab; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Rancho Mirage, California • San Francisco, California • New Haven, Connecticut + 14 more

Conditions: Shift-work Disorder
Interventions: Active phototherapy, Control phototherapy, Cognitive Behavioral Therapy (CBT), Sleep education control; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Interventions: IBI363; Drug
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hidradenitis Suppurativa
Interventions: Topical roflumilast 0.3% foam; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Covington, Louisiana • New Orleans, Louisiana

Conditions: Feasibility, Diet, Healthy
Interventions: Super Chef: Family Fun in the Kitchen!; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Substance Use Disorders
Interventions: Advanced Emotion App, Basic Emotion App; Behavioral
Lead sponsor: Treatment Innovations; Industry
Eligibility: 18 Years to 26 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat; Radiation · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 37 Months to 21 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 174
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more

Conditions: Schizophrenia
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more

Conditions: Myeloma Multiple
Interventions: Off Drug Surveillance; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Little Rock, Arkansas • Iowa City, Iowa • New York, New York + 1 more

Conditions: Neoplasms
Interventions: GSK3368715; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Philadelphia, Pennsylvania + 2 more

Conditions: Multiple Myeloma
Interventions: Autologous Genetically modified T cells; Genetic
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Leukaemia, Lymphocytic, Chronic
Interventions: Ofatumumab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Carcinoma, Hepatocellular
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Search by objective public record fields.

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

4 mA tDCS, Estrogen, and Leg Muscle Fatigability

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Role of Sleep Reactivity in Shift Work Disorder

A Study of IBI363 in Subjects with Advanced Solid Malignancies

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

Super Chef - an Online Program Promoting the Mediterranean Dietary Pattern to Lower Income Families

Automated Assessment Using Facial Coding

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Limited-duration Teclistamab

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Redirected Auto T Cells for Advanced Myeloma

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Trial of Indomethacin in Chronic Pancreatitis